Krishnamurthy, A., Wang, H., Rhee, J. C., Davar, D., Moy, R. H., Ratner, L., Christner, S. M., Holleran, J. L., Deppas, J., Sclafani, C., Schmitz, J. C., Gore, S., Chu, E., Bakkenist, C. J., Beumer, J. H., & Villaruz, L. C. (2025). Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406). Cancer Chemotherapy and Pharmacology, 95(1). https://doi.org/10.1007/s00280-024-04745-6

El-Sadoni, M., Shboul, S. A., Alhesa, A., Shahin, N. A., Alsharaiah, E., Ismail, M. A., Ababneh, N. A., Alotaibi, M. R., Azab, B., & Saleh, T. (2023). A three-marker signature identifies senescence in human breast cancer exposed to neoadjuvant chemotherapy. Cancer Chemotherapy and Pharmacology, 91(4), 345–360. https://doi.org/10.1007/s00280-023-04523-w

Moy, R. H., Greally, M., Chou, J. F., Li, J., Desai, A. M., Chalasani, S. B., Won, E., Kelsen, D. P., Ilson, D. H., Janjigian, Y. Y., Capanu, M., & Ku, G. Y. (2022). Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma. Cancer Chemotherapy and Pharmacology, 89(2), 255–265. https://doi.org/10.1007/s00280-021-04384-1

Tan, A. R., Chan, N., Kiesel, B. F., Stein, M. N., Moss, R. A., Malhotra, J., Aisner, J., Shah, M., Gounder, M., Lin, H., Kane, M. P., Lin, Y., Ji, J., Chen, A., Beumer, J. H., & Mehnert, J. M. (2021). A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies. Cancer Chemotherapy and Pharmacology, 89(1), 49–58. https://doi.org/10.1007/s00280-021-04350-x